HIGHLIGHTS
- who: Alexandra Chera from the Shahid Beheshti University of Medical Sciences, Iran have published the article: Thyroid-related adverse events induced by immune checkpoint inhibitors, in the Journal: (JOURNAL)
- future: A better understanding of the irAEs pathogenesis through further studies is required.
SUMMARY
Anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal_antibodies (e_g ipilimumab), anti-programmed death 1 (PD-1) monoclonal_antibodies (e_g pembrolizumab, nivolumab, cemiplimab) and anti-PD-1 ligand (PD-L1) monoclonal_antibodies (e_g avelumab, atezolizumab, durvalumab) are the types of ICIs used at the moment. Common irAEs associated with . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.